{"id":"W2589237569","doi":"10.1186/s13045-017-0417-z","title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":427,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Incyte","keywords":"Ruxolitinib; Medicine; Placebo; Myelofibrosis; Internal medicine; Randomized controlled trial; Population; Adverse effect; Clinical endpoint; Surgery; Pathology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007826844,0.000486333,0.003791041,0.0001375887,0.0005679564,0.00009103011,0.0003291946,0.0002936817,0.0001994584],"category_scores_gemma":[0.0003379865,0.0002091211,0.0006683623,0.00004307849,0.0006786233,0.0001842534,0.00004641197,0.0003310748,0.00001592466],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002961872,"about_ca_system_score_gemma":0.0008540811,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004846359,"about_ca_topic_score_gemma":0.0002951335,"domain_scores_codex":[0.9970184,0.0003935137,0.00129085,0.000397113,0.000389692,0.0005104381],"domain_scores_gemma":[0.991873,0.003156126,0.00339795,0.0006491172,0.0006270164,0.0002967551],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.877329,0.006135759,0.1049089,0.00001951321,0.006400684,0.0004961859,0.0002794787,0.000001613063,0.000003395812,0.001300758,0.0005503158,0.00257436],"study_design_scores_gemma":[0.9441233,0.04277953,0.002675061,0.0002606714,0.006478048,0.0006578089,0.00009602356,0.00001135797,0.0005167343,0.0001213925,0.00209031,0.0001897858],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.981016,0.0006180169,0.0003324472,0.007652587,0.0006862181,0.009047818,0.00008063742,0.00001459246,0.0005516796],"genre_scores_gemma":[0.9932414,0.0004815622,0.002598553,0.0005543439,0.0006968546,0.002123962,0.0001274673,0.00005018677,0.0001256432],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1022339,"threshold_uncertainty_score":0.8527711,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03706328763014617,"score_gpt":0.3607162889532588,"score_spread":0.3236530013231126,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}